S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS

• M. Dickinson,
• C. Carlo-Stella,
• F. Morschhauser,
• E. Bachy,
• P. Corradini,
• G. Iacoboni,
• C. Khan,
• T. Wróbel,
• F. Offner,
• M. Trněný,
• S.-J. Wu,
• G. Cartron,
• M. Hertzberg,
• A. Sureda,
• D. Perez-Callejo,
• L. Lundberg,
• J. Relf,
• E. Clark,
• K. Humphrey,
• M. Hutchings

Affiliations

M. Dickinson

1 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC, Australia

C. Carlo-Stella

2 Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

F. Morschhauser

3 Hôpital Claude Huriez and CHU de Lille, Lille

E. Bachy

4 Centre Hospitalier Lyon-Sud, Lyon, France

P. Corradini

5 Università degli Studi di Milano and Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCSS) Istituto Nazionale dei Tumori, Milan, Italy

G. Iacoboni

6 Vall d’Hebron University Hospital, Barcelona, Spain

C. Khan

7 Allegheny Health Network, Pittsburgh, PA, United States of America

T. Wróbel

8 Uniwersytet Medyczny we Wrocławiu, Wroclaw, Poland

F. Offner

9 Universitair Ziekenhuis Gent, Ghent, Belgium

M. Trněný

10 Charles University Hospital, Prague, Czechia

S.-J. Wu

11 National Taiwan University Hospital, Taipei, Taiwan

G. Cartron

12 CHU de Montpellier, Montpellier, France

M. Hertzberg

13 Prince of Wales Hospital and University of New South Wales, Sydney, NSW, Australia

A. Sureda

14 Institut Català d’Oncologia Hospital, Barcelona, Spain

D. Perez-Callejo

15 F. Hoffmann-La Roche Ltd, Basel, Switzerland

L. Lundberg

15 F. Hoffmann-La Roche Ltd, Basel, Switzerland

J. Relf

16 Roche Products Ltd, Welwyn Garden City, United Kingdom

E. Clark

16 Roche Products Ltd, Welwyn Garden City, United Kingdom

K. Humphrey

16 Roche Products Ltd, Welwyn Garden City, United Kingdom

M. Hutchings

17 Rigshospitalet, Copenhagen, Denmark